Boiron SA
PAR:BOI

Watchlist Manager
Boiron SA Logo
Boiron SA
PAR:BOI
Watchlist
Price: 30.2 EUR Market Closed
Market Cap: 530m EUR

Relative Value

The Relative Value of one BOI stock under the Base Case scenario is 35.12 EUR. Compared to the current market price of 30.2 EUR, Boiron SA is Undervalued by 14%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BOI Relative Value
Base Case
35.12 EUR
Undervaluation 14%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
77
vs Industry
72
Median 3Y
1.2
Median 5Y
1.3
Industry
2.7
Forward
1
vs History
11
vs Industry
27
Median 3Y
19.7
Median 5Y
19.7
Industry
21.6
Forward
12.9
vs History
79
vs Industry
38
Median 3Y
12.3
Median 5Y
12.3
Industry
16.9
vs History
77
vs Industry
20
Median 3Y
26.6
Median 5Y
26.6
Industry
22.9
vs History
38
vs Industry
58
Median 3Y
1.3
Median 5Y
1.4
Industry
2.3
vs History
47
vs Industry
78
Median 3Y
0.9
Median 5Y
0.9
Industry
3
Forward
0.9
vs History
52
vs Industry
83
Median 3Y
1.3
Median 5Y
1.3
Industry
5.6
vs History
46
vs Industry
41
Median 3Y
6.6
Median 5Y
6.4
Industry
13.4
Forward
5.8
vs History
19
vs Industry
32
Median 3Y
12.6
Median 5Y
11.7
Industry
16.7
Forward
9.9
vs History
60
vs Industry
41
Median 3Y
10.1
Median 5Y
10.1
Industry
16.1
vs History
60
vs Industry
27
Median 3Y
16.9
Median 5Y
16.9
Industry
18.9
vs History
41
vs Industry
65
Median 3Y
1
Median 5Y
1
Industry
2

Multiples Across Competitors

BOI Competitors Multiples
Boiron SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Boiron SA
PAR:BOI
524.3m EUR 1 27.1 6.6 17.7
US
Eli Lilly and Co
NYSE:LLY
982.7B USD 16.5 53.4 35.8 38.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
528.3B USD 5.7 21 17.2 22.3
CH
Roche Holding AG
SIX:ROG
276B CHF 4.5 29.3 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
218.7B GBP 5 31.1 108.8 159.3
CH
Novartis AG
SIX:NOVN
220B CHF 4.9 19 12.1 15.6
US
Merck & Co Inc
NYSE:MRK
273.7B USD 4.3 14.4 10.2 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.4 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
146.1B USD 2.3 14.9 7.5 10.3
P/E Multiple
Earnings Growth PEG
FR
Boiron SA
PAR:BOI
Average P/E: 25.2
27.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.4
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
21
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.3
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.1
37%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Boiron SA
PAR:BOI
Average EV/EBITDA: 400.6
6.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.8
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17.2
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12.1
6%
2
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Boiron SA
PAR:BOI
Average EV/EBIT: 1 714.1
17.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.4
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.3
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5